You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-DYRK-Leucettinib-21
Leucettinib-21

Chemical Structure : Leucettinib-21

CAS No.: 2732859-75-3

Leucettinib-21 (LCTB-21)

Catalog No.: PC-21506Not For Human Use, Lab Use Only.

Leucettinib-21 is a potent, selective DYRKs and CLKs kinases with IC50 of 2.4, 6.7, 12, 33, and 5 nM for DYRK1A, DYRK1B, CLK1, CLK2, and CLK4, respectively.

Packing Price Stock Quantity
50 mg Get quote
100 mg Get quote
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

Leucettinib-21 is a potent, selective DYRKs and CLKs kinases with IC50 of 2.4, 6.7, 12, 33, and 5 nM for DYRK1A, DYRK1B, CLK1, CLK2, and CLK4, respectively.
Leucettinib-21 weakly inhibits DYRK2/3/4, and CLK3 (IC50=200-1000 nM), inhibits only weakly inhibits some kinases (RPS6KA4, CDK7, DMPK) in a panel of 468 kinases at 1 uM.
Leucettinib-21 shows Kd values of 0.272 and 0.388 nM for DYRK1A and CLK1, respectively, 26 and 22 times lower than that for Leucettine L41 (Cat#PC-61025).
Leucettinib-21 triggers a dose-dependent inhibition of endogenous DYRK1A catalytic activity in HT-22 mouse hippocampal neuronal cells with IC50 of 36 nM.
Leucettinib-21 (0-10 uM) inhibits the phosphorylation of reported DYRK1A substrate sites in SH-SY5Y cells, such as Thr286-cyclin D1 and Thr212-Tau, protects cyclin D1 from proteolytic degradation, leading to its accumulation.
Leucettinib-21 (0.4 mg/kg, oral gavage daily, 10 days) corrects memory disorders in the Down syndrome mouse model Ts65Dn, a classical animal model of Down syndrome (DS).

Physicochemical Properties

M.Wt 358.46
Formula C18H22N4O2S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

(R,Z)-5-(benzo[d]thiazol-6-ylmethylene)-2-((1-methoxy-4-methylpentan-2-yl)amino)-3,5-dihydro-4H-imidazol-4-one

References

1. Mattias F. Lindberg, et al. Journal of Medicinal Chemistry, 2023.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: